Patients who have the same condition sometimes pay different out-of-pocket costs for their medications, but when is this differential more appropriate? Our webinar addressed these questions and identified some of the ethical, legal and economic issues with variable copays based on NPC research. 

NPC President Dan Leonard tackles variable copays in his latest commentary for Chain Drug Review. In it, he considers when variable cost-sharing is less acceptable for patients who require higher-tier formulary medications and highlights recent NPC research examining patient cost-sharing.

A new white paper highlights survey findings from payers and providers on what types of evidence are most important to them when it comes to making population coverage decisions for formularies and care pathways.